Close Menu

NEW YORK – Bristol-Myers Squibb announced that although a Phase III trial involving nivolumab (Opdivo) and chemoradiation didn't meet its primary endpoint of progression-free survival in patients with MGMT methylated brain cancer, the study will continue to assess if the treatment extends survival.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.